{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"}],"units":"Participants"}],"title":"By intention to treat"},{"categories":[{"measurements":[{"groupId":"OG000","value":"29"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"}],"units":"Participants"}],"title":"Excluding early non-relapse deaths"}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"}],"units":"Participants"}],"description":"To be considered a treatment efficacy success at 1 year posttransplant, the patient's bone marrow must demonstrate complete hematological remission, absence of Philadelphia chromosomes, and not satisfy any of the criteria for treatment failure (\\>/= 1% aberrantly expressing marrow blasts by multiparameter flow cytometry, \\>5% BCR/ABL in marrow by fluorescent in situ hybridization, or \\>1 log rise in peripheral blood BCR/ABL by quantitative polymerase chain reaction (PCR) since day 80).","groups":[{"description":"Beginning after engraftment and blood count recovery (21 to 28 days after allogeneic stem cell transplant), patients with imatinib-sensitive leukemia receive imatinib mesylate PO once daily until day 80 and then nilotinib PO twice daily on days 81-445. Patients with imatinib-resistant leukemia receive nilotinib PO twice daily beginning after engraftment and blood count recovery until day 445. Treatment continues in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Prophylactic Inhibition of BCR-ABL Tyrosine Kinase)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The analysis population was considered in two ways: first the number of treatment success in the entire cohort (by \"intention to treat\"), and second the number of treatment successes among only those patients who did not die before 1 year from non-relapse mortality.","reportingStatus":"POSTED","timeFrame":"Up to 1 year","title":"The Proportion of Patients at 1 Year With Treatment Efficacy Success","type":"SECONDARY","unitOfMeasure":"Participants"}